Francine presently spearheads the IND-enabling initiative at ProteinQure, focusing on advancing the lead asset PQ203, a peptide drug conjugate, through the developmental pipeline. Previously, she made significant contributions at Northern Biologics, a clinical-stage biotechnology firm specializing in cancer immunotherapies, where she contributed to the advancement of their lead asset through Phase 2 clinical trials. Francine completed her PhD at the University of Toronto and conducted her postdoctoral training at Harvard Medical School.